Vaccines for Healthcare-associated Infections: Promise and Challenge

Clinical Infectious Diseases

Volumn 63, Issue 5, 2016, Pages 657-662

  Knisely, Jane M ^a   Liu, Baoying ^a   Ranallo, Ryan T ^a   Zou, Lanling ^a   Weinstein, Robert A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

antibiotic resistance; Clostridium difficile; healthcare associated infections; Staphylococcus aureus; vaccines

Indexed keywords

BACTERIAL VACCINE; FUNGUS VACCINE; STAPHYLOCOCCUS VACCINE; VACCINE;

ARTICLE; CANDIDA; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; GRAM NEGATIVE INFECTION; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VACCINATION; ANTIBIOTIC RESISTANCE; CROSS INFECTION; MICROBIOLOGY; PSEUDOMEMBRANOUS COLITIS;

BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84995482138     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw333     Document Type: Article

References (59)

1. Magill SS, Edwards JR, Beldavs ZG, et al. Prevalence of antimicrobial use in US acute care hospitals, May-September 2011. JAMA 2014; 312:1438-46.
2. Centers for Disease Control and Prevention. Antibiotic resistant threats in the United States, 2013. Available at: www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 1 March 2016.
3. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-34.
4. The White House. National strategy for combating antibiotic-resistant bacteria, 2014. Available at: https://www.whitehouse.gov/sites/default/files/docs/carb-national-strategy.pdf. Accessed 1 March 2016.
5. The White House. National action plan for combating antibiotic-resistant bacteria, 2015. Available at: https://www.whitehouse.gov/sites/default/files/docs/national-action-plan-for-combating-antibotic-resistant-bacteria.pdf. Accessed 1 March 2016.
6. O'Neill J. Vaccines and alternative approaches: reducing our dependence on antimicrobials, 2016. Available at: http://amr-review.org/sites/default/files/Vaccines% 20and%20alternatives-v4-LR.pdf. Accessed 1 March 2016.
7. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354:1455-63.
8. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015; 15:301-9.
9. Lessa FC, Winston LG, McDonald LC, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:2369-70.
10. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-49.
11. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-9.
12. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
13. Theriot CM, Young VB. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol 2015; 69:445-61.
14. Kuehne SA, Collery MM, Kelly ML, et al. Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis 2014; 209:83-6.
15. Schwan C, Stecher B, Tzivelekidis T, et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog 2009; 5:e1000626.
16. Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55 (suppl 2):S77-87.
17. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55(suppl 2):S88-92.
18. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-93.
19. Ghose C, Kelly CP. The prospect for vaccines to prevent Clostridium difficile infection. Infect Dis Clin North Am 2015; 29:145-62.
20. Leuzzi R, Adamo R, Scarselli M. Vaccines against Clostridium difficile. Hum Vaccin Immunother 2014; 10:1466-77.
21. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001; 69:988-95.
22. Sanofi. Safety, tolerability, and immunogenicity of a Clostridium difficile toxoid vaccine in healthy elderly volunteers (NCT00214461). Available at: https://clinicaltrials.gov/ct2/show/NCT00214461?term=NCT00214461&rank=1. Accessed 7 March 2016.
23. Sanofi. Safety, tolerability, and immunogenicity study of a Clostridium difficile toxoid vaccine in healthy adult volunteers (NCT00127803). Available at: https://clinicaltrials.gov/ct2/show/NCT00127803?term=NCT00127803&rank=1. Accessed 7 March 2016.
24. Sanofi. Phase I randomized, placebo-controlled, double-blind, dose ranging study, safety, tolerability and immunogenicity (NCT00772954). Available at: https://clinicaltrials.gov/ct2/show/NCT00772954?term=NCT00772954&rank=1. Accessed 7 March 2016.
25. Sanofi Pasteur. Study of a candidate Clostridium difficile toxoid vaccine in healthy adult subjects aged 40 to 75 years in Japan (NCT01896830). Available at: https://clinicaltrials.gov/ct2/show/NCT01896830?term=NCT01896830&rank=1. Accessed 7 March 2016.
26. Sanofi Pasteur. Study of different formulations of a Clostridium difficile toxoid vaccine given at three different schedules in adults (NCT01230957). Available at: https://clinicaltrials.gov/ct2/show/NCT01230957?term=NCT01230957& rank=1. Accessed 7 March 2016.
27. Sanofi Pasteur. Study of a candidate Clostridium difficile toxoid vaccine (Cdiffense) in subjects at risk for C. difficile infection (NCT01887912). Available at: https://clinicaltrials.gov/ct2/show/NCT01887912?term=NCT01887912&rank=1. Accessed 7 March 2016.
28. Pfizer. A study to investigate a Clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine (NCT02052726). Available at: https://clinicaltrials.gov/ct2/show/NCT02052726?term=NCT02052726&rank=1. Accessed 7 March 2016.
29. Pfizer. Evaluation of a 3-dose vaccination regimen with one of three ascending dose levels of Clostridium difficile vaccine with or without adjuvant in healthy adults aged 50 to 85 years (NCT01706367). Available at: https://clinicaltrials.gov/ct2/show/NCT01706367?term=NCT01706367&rank=1. Accessed 7 March 2016.
30. Pfizer. A study to investigate two 3-dose schedules of a Clostridium difficile vaccine in healthy adults aged 65 to 85 years (NCT02561195). Available at: https://clinicaltrials.gov/ct2/show/NCT02561195?term=NCT02561195&rank=1. Accessed 7 March 2016.
31. Valneva Austria GmbH. An open-label study assessing safety, immunogenicity and dose response of IC84 (NCT01296386). Available at: https://clinicaltrials.gov/ct2/show/NCT01296386?term=NCT01296386&rank=1. Accessed 7 March 2016.
32. Valneva. Valneva's Clostridium difficile vaccine candidate. Available at: https://wwwvalnevacom/?page=85. Accessed 1 March 2016.
33. Valneva Austria GmbH. Dose-confirmation, immunogenicity and safety study of the Clostridium difficile vaccine candidate VLA84 in healthy adults aged 50 years and older. phase II study (NCT02316470). Available at: https://clinicaltrials.gov/ct2/show/NCT02316470?term=NCT02316470&rank=1. Accessed 7 March 2016.
34. Lee BY, Popovich MJ, Tian Y, et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010; 28:5245-53.
35. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128:764-70.
36. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009; 7:629-41.
37. Dantes R, Mu Y, Belflower R, et al. National burden of invasive methicillinresistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013; 173:1970-8.
38. Rogers DE, Melly MA. Speculations on the immunology of staphylococcal infections. Ann N Y Acad Sci 1965; 128:274-84.
39. Fattom AI, Horwith G, Fuller S, et al. Development of Staph VAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004; 22:880-7.
40. Fattom A, Matalon A, Buerkert J, et al. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum Vaccin Immunother 2015; 11:632-41.
41. Fowler VG, Allen KB, Moreira ED, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013; 309:1368-78.
42. McNeely TB, Shah NA, Fridman A, et al. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors. Hum Vaccin Immunother 2014; 10:3513-6.
43. Pfizer. Evaluation of a single vaccination with one of three ascending dose levels of a 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy adults aged 18 to <65 years (NCT01364571). Available at: https://clinicaltrials.gov/ct2/show/record/NCT01364571?term=SA4Ag&rank=1. Accessed 7 March 2016.
44. Pfizer. Safety and efficacy of SA4Ag vaccine in adults having elective posterior instrumented lumbar spinal fusion procedure (STRIVE) (NCT02388165). Available at: https://clinicaltrials.gov/ct2/show/NCT02388165. Accessed 7 March 2016.
45. Bagnoli F, Bertholet S, Grandi G. Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. Front Cell Infect Microbiol 2012; 2:16.
46. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:560-7.
47. National Institute of Allergy and Infectious Diseases. Overcoming challenges in Staphylococcus aureus vaccine development. Available at: https://www.niaidnihgov/about/organization/dmid/Documents/staphWorkshoppdf2013. Accessed 1 March 2016.
48. Lucero CA, Hageman J, Zell ER, et al. Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States. Vaccine 2009; 27:5061-8.
49. Valneva Austria GmbH. Confirmatory phase II/III study assessing efficacy, immunogenicity and safety of IC43 (NCT01563263). Available at: https://clinicaltrials.gov/ct2/show/NCT01563263?term=NCT01563263&rank=1. Accessed 7 March 2016.
50. Glyco Vaxyn AG. Vaccine against Escherichia coli infection (NCT02289794). Available at: https://clinicaltrials.gov/ct2/show/NCT02289794?term=NCT 02289794&rank=1. Accessed 7 March 2016.
51. Kim OY, Hong BS, Park KS, et al. Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol 2013; 190:4092-102.
52. Lee WH, Choi HI, Hong SW, et al. Vaccination with Klebsiella pneumoniaederived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity. Exp Mol Med 2015; 47:e183.
53. Chen W. Current advances and challenges in the development of Acinetobacter vaccines. Hum Vaccin Immunother 2015; 11:2495-500.
54. Pevion Biotech Ltd. Safety and immunogenicity study of a virosomal vaccine against recurrent vulvovaginal Candida infection (NCT01067131). Available at: https://clinicaltrials.gov/ct2/show/NCT01067131?term=NCT01067131&rank=1. Accessed 7 March 2016.
55. Nova Digm Therapeutics. Safety, tolerability, immunogenicity and efficacy of NDV-3A vaccine in preventing recurrent vulvovaginal candidiasis (NCT01926028). Available at: https://clinicaltrials.gov/ct2/show/NCT01926028? term=NCT01926028&rank=1. Accessed 7 March 2016.
56. Yeaman MR, Filler SG, Schmidt CS, et al. Applying convergent immunity to innovative vaccines targeting Staphylococcus aureus. Front Immunol 2014; 5:463.
57. Morrison C. Antibacterial antibodies gain traction. Nat Rev Drug Discov 2015; 14:737-8.
58. Aridis. Safety, pharmacokinetics and efficacy of KBSA301 in severe pneumonia (S. aureus). Available at: https://clinicaltrials.gov/ct2/show/NCT01589185? term=AR-301&rank=1. Accessed 7 March 2016.
59. Weisman LE, Thackray HM, Steinhorn RH, et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011; 128:271-9.